China Nuclear Imaging Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

China's nuclear imaging market encompasses both imaging equipment, including positron emission tomography (PET) and single-photon emission computed tomography (SPECT) systems, and the radiopharmaceuticals used to conduct these scans. Valued at approximately USD 0.49 billion in 2025, the market is on a steady upward trajectory with projections placing it near USD 930 million by the early 2030s. Within the broader Asia-Pacific nuclear imaging devices market, valued at roughly USD 1.6 billion in 2025, China commands the largest share, reflecting its outsized role in regional healthcare technology adoption.

• •China holds approximately 38.5% of Asia-Pacific nuclear imaging devices revenue, making it the region's dominant market
• •The market encompasses PET and SPECT imaging systems, radiopharmaceuticals, and associated molecular diagnostic services

Government initiatives have been a central catalyst, with policies aimed at expanding nuclear medicine infrastructure and promoting domestic production of imaging equipment and radiopharmaceuticals. An aging population and rising incidence of cancer, neurological disorders, and cardiovascular disease are increasing demand for advanced diagnostic imaging. Meanwhile, improved healthcare reimbursement frameworks and the construction of new nuclear medicine departments across provincial hospitals are expanding access to these technologies beyond major urban centers.

• •Government support for nuclear medicine infrastructure development and localization of imaging equipment and radiopharmaceutical supply chains
• •Rising prevalence of cancer and cardiovascular disease, combined with China's aging demographic, is driving diagnostic imaging demand
• •Expanding healthcare reimbursement and hospital infrastructure investment is broadening access in Tier 2 and Tier 3 cities

The nuclear imaging market in China is typically segmented by product type, PET scanners, SPECT scanners, and hybrid imaging systems, and by application, including oncology, cardiology, and neurology. The equipment segment dominates current market value, though radiopharmaceuticals represent a high-growth sub-sector within the broader nuclear medicine space. Geographically, Eastern China and major metropolitan areas such as Beijing, Shanghai, and Guangzhou lead in installed base, while Western and Central provinces are emerging as the next phase of expansion as healthcare networks decentralize.

• •Key application areas include oncology (oncology staging and therapy monitoring), cardiology (myocardial perfusion imaging), and neurology (brain metabolism and dementia diagnostics)
• •Eastern China and top-tier cities hold the largest installed base of nuclear imaging systems, with Western and Central regions representing the fastest-growing deployment areas
• •The broader nuclear medicine segment, including therapeutics, is projected to grow at a significantly higher compound rate than equipment alone

What are the recent trends and outlook?

Looking ahead, the market is expected to benefit from continued policy support for domestic manufacturing, ongoing hospital infrastructure upgrades, and gradual expansion of nuclear medicine services into smaller cities. Digital integration, including AI-assisted image interpretation and hybrid imaging modalities combining PET with CT or MRI, is anticipated to drive demand for next-generation systems. The radiopharmaceutical supply chain, historically reliant on imported isotopes, is expected to see meaningful domestic capacity growth, supporting long-term market expansion. Overall, the China nuclear imaging market is positioned for sustained above-average growth through the end of the decade.

• •Domestic production of imaging equipment and radiopharmaceuticals is expected to accelerate under government-supported localization policies
• •AI-enabled image analysis and hybrid imaging systems (PET/CT, PET/MRI) are emerging as key technology trends shaping future procurement decisions
• •The market's multi-year outlook remains strong, with continued expansion supported by healthcare infrastructure investment, demographic trends, and technological advancement